Article
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
The Journal of clinical investigation - 3 Apr 2023
Salmón Marina, Álvarez-Díaz Ruth, Fustero-Torre Coral, Brehey Oksana, Lechuga Carmen G, Sanclemente Manuel, Fernández-García Fernando, López-García Alejandra, Martín-Guijarro María Carmen, Rodríguez-Perales Sandra, Bousquet-Mur Emily, Morales-Cacho Lucía, Mulero Francisca, Al-Shahrour Fátima, Martínez Lola, Domínguez Orlando, Caleiras Eduardo, Ortega Sagrario, Guerra Carmen, Musteanu Monica, Drosten Matthias, Barbacid Mariano
Abstract excerpt
KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and the emergence of tumor resistance between genetic ablation of mutant Kras expression and pharmacological inhibition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.